v3.26.1
10-Q Fair value measurements and financial risk management (Tables)
3 Months Ended
Mar. 31, 2026
Fair Value Disclosures [Abstract]  
Schedule of assets and liabilities measured at fair value
As of December 31, 2025 and 2024, the Company’s financial instruments measured at fair value on a recurring basis were classified in the fair value hierarchy as follows:
As of December 31, 2025
Level 1
Level 2
Level 3
Total
Investments
$
— 
$
— 
$
— 
$
— 
Contingent consideration liabilities
— 
— 
3,358 
3,358 
$
— 
$
— 
$
3,358 
$
3,358 
As of December 31, 2024
Level 1
Level 2
Level 3
Total
Investments
$
— 
$
— 
$
1,713 
$
1,713 
Contingent consideration liabilities
— 
— 
6,147 
6,147 
$
— 
$
— 
$
7,860 
$
7,860 
Schedule of valuation methodologies and inputs
As of December 31, 2025 and 2024, the following valuation methodologies and significant unobservable inputs were used to derive the fair value measurements of the Company’s financial instruments measured at fair value on a recurring basis:
As of December 31,
Financial instrument
Valuation methodology
Level 3 input
2025
2024
Contingent consideration – EMMAC
Monte Carlo simulation
Timing of achievement
2 years
2 years
Probability of achievement
99.0 
%
99.0 
%
Investments
Adjusted estimated net asset fair value
Capitalization rate
N/A
8.9 
%
Schedule of aging of trade receivables
The following table presents the aging of the Company's trade accounts receivable as of March 31, 2026 and December 31, 2025:
As of
March 31, 2026
December 31, 2025
0 to 90 days
$
63,693 
$
66,649 
91 to 180 days
3,334 
3,572 
181 days +
3,633 
3,643 
Trade accounts receivable
$
70,660 
$
73,864